Effects, Safety, and Cost Efficacy of Controlled-Release Oxycodone for Pain Control in Transarterial Chemoembolization Therapy for Patients with Liver Cancers

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-11001416

Enrollment

Unknown

Registered

2011-07-07

Start date

2009-05-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

liver cancer

Interventions

B:20mg controlled-release oxycodone given from one hour before chemoembolization (TACE) therapy and every 12 hours until 48hours after TACE

A:10mg controlled-release oxycodone given from one hour before chemoembolization (TACE) therapy and every 12 hours until 48hours after TACE

C:placebo pills (containing 100 mg Vitamin C) given from one hour before chemoembolization (TACE) therapy and every 12 hours until 48hours after TACE

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: patients with age of 18 or older, scheduled for TACE

Exclusion criteria

Exclusion criteria: American Society of Anesthesiologists (ASA) physical status > III, known allergic or intolerant to CRO, pregnant, a history of drug abuse, history of long time opioid medication, history of postoperative nausea and vomiting (PONV), history of ileus, liver dysfunction defined as elevation of serum alanine aminotransferase and serum aspartate aminotransferase three times above the upper normal range.

Design outcomes

Primary

Measure	Time frame
pain score (NRS);	—

Secondary

Measure	Time frame
morphine consumption;life qualit;	—

Countries

China

Contacts

Public ContactJianhua Wang

wangjianhua2011@sina.com+86 21 64041990-3088

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026